A little late to the party, but saw a posting on GSK partnering with a company called Alnylam. As I understand it, the tech is supposed to make vaccine production better (and could thus become a standard procedure?).
So a few things.. - Will this send GSK's stock up or is this just a blip on the radar? - Is this really a good thing if Novartis and Roche (owner of Genentech) pulled out earlier...?